Six biotech companies that could revolutionize obesity treatments

Biotech companies around the world are producing new drugs to treat obesity, taking advantage of growing demand for GLP-1 agonist medication. Pharmaceutical giants such as Novo Nordisk, Lilly, Amgen and Pfizer already have successful drugs on the market. Now, six smaller biotech companies – Zealand Pharma, Altimmune, Viking Therapeutics, Jiangsu Hengrui Pharmaceuticals, Structure Therapeutics and Antag Therapeutics – are developing their own medications to treat obesity and diabetes. With drugs in various stages of clinical trials, these companies could soon join the larger players in the market.